Krysten Williams, head of global marketing and education at Heidelberg Engineering, describes what’s new in multimodal imaging and how Heidelberg plays a role in it, the company’s virtual academy, and they're promoting the “dynamic visualization” of the entire eye.
Hamadi El-Ayari, vice president, sales and marketing at Geuder AG, divulges details about the numerous product introductions the company is planning at the 2020 EURETINA virtual conference.
Prof. Anat Lowenstein of Tel Aviv University, Israel, discusses the innovative moves towards incorporating head-wearable devices in surgical theatres and the importance of improving outcomes in the management of AMD patients with home monitoring, a field particularly noteworthy during the COVID-19 pandemic.
Dr Tunde Peto explains that the rate of blindness from diabetes continues to increase by 8% annually and the only way to prevent this may well rest with well-planned, evidence-based services.
A port delivery system with ranibizumab with dosing every 24 weeks has been shown in a Phase III trial to be equivalent to monthly intravitreal ranibizumab injection to treat neovascular age-related macular degeneration, according to Dr Carl Regillo, who reported on behalf of the Archway Trial investigators.
Mehran Nouroozian, Regional Manager at Oertli for the Middle East Region, India, and Turkey at Oertli, shows off the company’s newest product additions during this year's virtual meeting.
Prof. Frank Holz, Chairman of the Department of Ophthalmology at the University of Bonn, Germany, highlights the topics, lectures, symposia and instructional courses that will take place at this year’s virtual EURETINA conference, and gives his insights on the hot topics of the dynamic retina field.
Heads-up surgery is moving into the next generation of vitreoretinal surgery, with novel technologies being developed for surgeons.
The first reported clinical results of a Phase I study following implantation of the 3-D neural interface retinal prosthesis showed it is safe in patients with end-stage retinitis pigmentosa.
Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.
Study offers a real-world scenario of a very specific, but frequent and crucial aspect of the care of patients with diabetes, suggests clinician
Investigational OCT system with AI-based image analysis holds promise
An interim analysis including data from almost 150 patients found an association between higher number of injections and increased risk of mild cognitive impairment.
Visual acuity outcomes at 6 months’ post-treatment were similar, regardless of the use of anti-VEGF therapy.
Modifier-25 same-day examinations are critical to the successful treatment and overall health and well being of these patients.
Measuring high-quality care cannot be a barrier to providing it, notes John T. Thompson, MD.
Study points to the possible role of addressing preprocedural anxiety
Investigators find that nanoparticles deliver gene therapy successfully in mice, rats
Automated assistance controls tremor, reduces fatigue, and helps avoid inadvertent injury
Agreement would include global rights for investigational treatment, risuteganib, expected to help reverse vision loss due to dry AMD
Evidence-based medicine can lead to personalized care, better results for patients
Ophthalmologists remain in touch with colleagues while maintaining social distancing
This ability would unlock possibilities for repairing tissue damaged by disease
Watchful waiting may prove to be beneficial in complicated cases
Intravitreal gene therapy continues to be well tolerated; shows robust efficacy
Novartis has announced positive topline results from the phase 3 KITE study of brolucizumab 6 mg versus aflibercept for patients with diabetic macular edema.
Though OCTA has become indispensable for managing macular degeneration and diabetic retinopathy, Robert L. Stamper, MD, explains why the technology must become more sophisticated and evolved before it reaches its full potential for glaucoma specialists.
Interim data update from first cohort using suprachoroidal delivery of RGX-314 expected by end of 2020
Results could provide a new preferred treatment paradigm for this population
Results of a prospective trial show the tool is ready for clinical use and potential deployment for remote telemedical use.
